Are you a Veteran of the United States Armed Forces?

Please complete a short survey about prostate cancer care for Veterans to help us learn what's working well and what needs improvement in the care Veterans receive.

Veterans prostate cancer care survey Complete the Survey

PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC

PSA doubling time (PSADT) among patients with castration-resistant prostate cancer (CRPC) strongly predicts their risk for metastatic disease and all-cause and cancer-specific mortality, according to a new study.

Read more.

Source: Renal and Urology News

Share